H. Lundbeck A/S Class A HLUN_A

Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction.

H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching the stock. The eptinezumab approval lands at a time when H. Lundbeck’s recent news flow also includes the randomization milestone in its Phase III bexicaserin epilepsy program and a plan to shift its US base to Greater Boston to build out a global innovation...